To put together our registering and reporting clinical research guidance, we used the following guidance:

• The UK Policy Framework for Health and Social Care Research
• The WHO Joint statement on public disclosure of results from clinical trials produced in 2017 and signed by some of the largest global funders, including charities. It sets out steps funders can take to support best practice in research transparency. The statement focusses on clinical trials, but the core principles e.g. developing policies, mandating timelines, and monitoring the uptake of these, can applied across the breadth of research our member’s fund.
• WHO guidance on the minimum amount of trial information that must appear in a register for a trial to be considered fully registered
• WHO guidance on International Standards for Clinical Trial Registries
• The draft of the WHO’s  guidance on best practice for clinical trials published in 2023
• Clinical trial transparency: A guide for policy makers by TranspariMED and others. TranspariMED is an advocacy group working to end evidence distortion in medicine, by holding actors to account and promoting policy solutions.
• NIHR’s guidance and standards for registration and governance
• NIHR Policy on clinical trial registration and disclosure of results
• The SPIRIT 2013 Statement on the minimum content of a clinical trial protocol 
• HRA’s transparency strategy produced by Make it Public. Make it Public is a campaign dedicated to research transparency. It was set up by HRA and includes experts from across the sector (including AMRC) as well as members of the public. There is a yearly Make it Public week during which transparency events/workshops are often held.

  ---

Back to Registering and reporting clinical research